Advanced Flower Capital reports progress on $5 million stock repurchase program

Advanced Flower Capital repurchased 1,060,089 common shares under its $5 million buyback program, leaving 22,468,755 shares outstanding; the program remains active until the $5 million limit is reached or May 4, 2027. In Q2 2026, revenue of $8.69 million beat the $8.0 million analyst forecast, while net investment income of $0.15 per share narrowly missed the $0.1533 estimate. Net investment income covered the $0.05 quarterly distribution three times, supporting the company’s capital-return capacity.

Analysis

The capital-return signal is meaningful relative to AFCG's sub-$100 million equity float, but its valuation impact depends on the discount to realizable NAV rather than a third-party fair-value estimate. Repurchases below NAV are mechanically accretive to NAV/share and can tighten an illiquid float, creating a near-term technical bid; they do not cure borrower concentration, non-accrual risk, or the limited exit options inherent in cannabis lending. The modest NII shortfall is more important than the revenue beat because the stock's valuation is driven by sustainable distributable earnings and credit marks.

Over the next 1-3 months, disclosed remaining buyback capacity and any insider purchases could support the shares disproportionately given thin trading volume. The 6-18 month determinant is whether AFCG can redeploy principal repayments into performing loans at comparable yields without raising loss reserves; a decline in portfolio yield or another migration to non-accrual status would overwhelm buyback accretion. Cannabis operators remain exposed to weak wholesale pricing, delayed regulatory reform, and constrained banking access, making AFCG more correlated to credit outcomes than to broad equity-market moves.

Consensus may overread the repurchase as evidence that management sees low credit risk. An alternative explanation is that buying discounted shares is the highest-return use of capital when new loan origination is constrained; that is favorable for per-share value but can also signal a shrinking earnings base. IIPR and MSOS can serve as imperfect read-throughs for cannabis-sector financing conditions, but AFCG's loan-level collateral and borrower-specific liquidity are the decisive variables.

Key Decisions for Investors

• Do not chase the post-buyback move; use a watch-level rather than a core position until the next filing discloses remaining authorization, average repurchase price, NAV/share, and non-accrual exposure. A sustained discount of more than 25% to reported NAV alongside continued repurchases would improve the long case.
• For a small-cap special-situations sleeve, consider a 1-2% long AFCG only on weakness below the reported repurchase-cost range or after confirmation that NII covers the distribution by at least 1.5x excluding one-time income. Target 20-30% upside from discount-to-NAV narrowing over 6-12 months; exit on a new material non-accrual, reserve build, or dividend coverage below 1.0x.
• Avoid using listed options or a short hedge in AFCG given likely poor liquidity. If cannabis credit stress broadens, reduce AFCG exposure and use MSOS or IIPR as more liquid sector-risk proxies rather than assuming the buyback provides downside protection.
• Set an earnings alert for portfolio yield, realized/unrealized credit losses, repayments versus originations, and NAV/share. A NAV decline exceeding 5% in a quarter or guidance implying lower recurring interest income would falsify the buyback-led accretion thesis.